Showing results (391-400 of 884) with videos related to
Sort By:
Pageof 89
Gastroenterology|December 31, 2003
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patientsJean-Frederic Colombel, Edward V Loftus, William J Tremaine, et al.Inflammatory Bowel Diseases|October 19, 2016
Increased Rates of Clostridium difficile Infection and Poor Outcomes in Patients with IBD with CytomegalovirusJeffrey D McCurdy, Felicity T Enders, Sahil Khanna, et al.The American Journal of Gastroenterology|May 5, 2026
Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease Treated With Risankizumab Versus Ustekinumab in the Phase 3B SEQUENCE StudyEdward V Loftus, Namita Joshi, Bruce E Sands, et al.Gut|December 15, 2016
Development of a Microscopic Colitis Disease Activity Index: a prospective cohort studyThomas G Cotter, Moritz Binder, Edward V Loftus, et al.Alimentary Pharmacology & Therapeutics|June 24, 2020
No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapySiddharth Singh, Jihoon Kim, Wenhong Zhu, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 30, 2013
Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysisSiddharth Singh, Abha Goyal Singh, Preet Paul Singh, et al.Gastrointestinal Endoscopy|July 17, 2019
Comparative accuracy of needle sizes and designs for EUS tissue sampling of solid pancreatic masses: a network meta-analysisAntonio Facciorusso, Sachin Wani, Konstantinos Triantafyllou, et al.Alimentary Pharmacology & Therapeutics|December 24, 2019
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's diseaseParambir S Dulai, Aurelien Amiot, Laurent Peyrin-Biroulet, et al.The American Journal of Gastroenterology|July 24, 2002
N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitisElena Ricart, William R Taylor, Edward V Loftus, et al.Journal of Crohn'S & Colitis|October 22, 2022
Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's DiseaseRishika Chugh, Manuel B Braga-Neto, Thomas W Fredrick, et al.Pageof 89